Cardinal Health (CAH) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Cardinal Health

NYSE•Healthcare•Medical Distribution

$226.34-6.20(-0.03%)After hours

Market Cap

$53.64B

P/E

31.3x

P/S

0.2x

Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile and non-sterile procedure kits. Additionally, it manufactures, prepares, and delivers radiopharmaceuticals; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

How this company scores

WeakMetricSide Score: 59/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Cash & Earnings Quality (23/25); weakest: Profitability (6/25).

Profitability6/25

Growth21/25

Balance Sheet & Red Flags9/25

Cash & Earnings Quality23/25

Strengths

Rising free cash flowCash-backed earningsConsistent growthImproving margins

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 32.7x5y range 13.1x – 156.2x

Currently near its 16-quarter median.

P/S · 0.2x5y range 0.1x – 0.2x

Currently above its 20-quarter median.

P/B · 14.7x5y range 10.7x – 14.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $53.64B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $254.25B
Q. Revenue: $63.86B
TTM EBITDA: $3.48B
TTM Op. Income: $2.61B
Q. Op. Income: $729.00M
TTM Net Income: $1.71B
Q. Net Income: $394.00M
EPS: N/A
Shares Out.: $237.00M

$254.25B in TTM revenue grew 14.2% YoY, reaching $63.86B last quarter. TTM EBITDA of $3.48B and TTM operating income of $2.61B show growth is flowing through to the bottom line. TTM net income of $1.71B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 1.8%
Op. Margin: 1.1%
Net Margin: 0.6%

Op. margin of 1.1% is up 0.4% YoY — cost efficiency is improving. Net margin at 0.6% Over the past year, operating margin is up 60% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 32.7x
P/S Ratio: 0.2x
P/B Ratio: N/A

At 32.7x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 0.2x and P/B of 0.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 3 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $57.30B
Cash: $4.86B
Long-Term Debt: $7.00B
Book Value: $-2.88B
D/E Ratio: N/A
Debt/EBITDA: 6.3

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

TTM Free Cash Flow: $4.53B
FCF Margin: 1.8%
FCF / Net Income: 2.6

TTM FCF of $4.53B. The FCF / Net Income ratio of 2.6x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 145% — an improving trend.